VivoSeq
Other

Recurrent Ganglioneuroblastoma

5

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Recurrent Ganglioneuroblastoma is an early-stage landscape with 5 programs across 4 companies. The most active players are United Therapeutics, Bristol-Myers Squibb, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

United Therapeutics logo

United Therapeutics

1 program

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

PreclinicalSanofi logo

Sanofi

1 program

PreclinicalM

Meitheal

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

3 of 5 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody120%Protein / enzyme120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

1

clinical trials

Not yet recruiting1 · 100%

Clinical Trials

Trial Activity

Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy
Not yet recruiting·National Cancer Institute (NCI)·Preclinical·NCT07437963·76 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)